Free Newsletter
Which merger's better, Merck's or Pfizer's?
It's striking--bordering on shocking--how investors have reacted differently to the megamergers by Pfizer and Merck, Motley Fool says. Merck traded down right after the announcement, but investors have bid up the stock by 17 percent since Merck announced it would by Schering; conversely, Pfizer's shares are down 18.3 percent. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: